Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population

PURPOSE: Sunitinib and pazopanib are multitargeted tyrosine kinase inhibitors (TKIs) that act against vascular endothelial growth factor receptors and are standard first-line treatment options for metastatic clear cell renal cell carcinoma (ccRCC). The Brazilian public health system diverges from th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Glob Oncol
Main Authors: Isaacsson Velho, Pedro, Nardo, Mirella, Souza, Manoel Carlos Leonardi de Azevedo, Bonadio, Renata R.C. Colombo, Marta, Guilherme Nader, Muniz, David Q.B., Bastos, Diogo Assed, Dzik, Carlos
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
Original Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7010438/
https://ncbi.nlm.nih.gov/pubmed/30199304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JGO.18.00073
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados